Compare · CNTQ vs TMO
CNTQ vs TMO
Side-by-side comparison of Chardan NexTech Acquisition 2 Corp. (CNTQ) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- CNTQ operates in Miscellaneous, while TMO operates in Industrials - the two are in different parts of the market.
- TMO is the larger of the two at $174.49B, about 1104.6x CNTQ ($158.0M).
- TMO has hit the wire 6 times in the past 4 weeks while CNTQ has been quiet.
- TMO has more recent analyst coverage (25 ratings vs 0 for CNTQ).
- Company
- Chardan NexTech Acquisition 2 Corp.
- Thermo Fisher Scientific Inc
- Price
- $13.79-9.16%
- $469.57+0.63%
- Market cap
- $158.0M
- $174.49B
- 1M return
- -
- -4.31%
- 1Y return
- -
- +11.45%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 6
- Recent ratings
- 0
- 25
Chardan NexTech Acquisition 2 Corp.
Chardan NexTech Acquisition 2 Corp. intends to enter into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. The company was incorporated in 2020 and is based in New York, New York.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest CNTQ
- SEC Form SC 13D/A filed by Chardan NexTech Acquisition 2 Corp. (Amendment)
- Chardan NexTech Acquisition 2 Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities
- Chardan NexTech Acquisition 2 Corp. filed SEC Form 8-K: Other Events
- Chardan NexTech Acquisition 2 Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events
- Chardan NexTech Acquisition 2 Corp. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form EFFECT filed by Chardan NexTech Acquisition 2 Corp.
- SEC Form DEFA14A filed by Chardan NexTech Acquisition 2 Corp.
- SEC Form 8-K filed by Chardan NexTech Acquisition 2 Corp.
- SEC Form S-3 filed by Chardan NexTech Acquisition 2 Corp.
- Chardan NexTech Acquisition 2 Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
Latest TMO
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Thermo Fisher Scientific Reports First Quarter 2026 Results
- AI-Powered Pharma Manufacturing Signals Scalable Efficiency, Long-Term Cost Advantages
- Thermo Fisher Scientific Expands Global Biobank Leadership Through Strategic Collaboration with PRECISE-SG100K Singapore to Advance Population-Scale Proteomics
- SEC Form DEFA14A filed by Thermo Fisher Scientific Inc
- SEC Form DEF 14A filed by Thermo Fisher Scientific Inc
- Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, April 23, 2026
- SEC Form 4 filed by Sperling Scott M
- SEC Form 4 filed by Keith R. Alexandra
- SEC Form 4 filed by Lynch Karen S